Short answer
Moderna (MRNA) filed its Q2 2025 10-Q quarterly report on Aug 1, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $142M (down 41.1% year over year) with net income of −$825M.
Q2 2025 key financials · XBRL
- Revenue
- $142M
- −41.1% YoY · +31.5% QoQ
- Net income
- −$825M
- +35.5% YoY · +15.0% QoQ
- Operating margin
- -638.7%
- EPS (diluted)
- −$2.12
- +36.5% YoY · +15.9% QoQ
Source: XBRL data from the Moderna (MRNA) Q2 2025 10-Q on SEC EDGAR. USD.
Moderna Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New patent infringement lawsuits by GSK filed July 2025 in Unified Patent Court covering Spikevax and mRESVIA RNA delivery technology
- Updated patent risk: Arbutus lawsuit trial rescheduled to March 9, 2026, impacting COVID vaccine manufacture and sales
- Most impactful legal risk: Pending Alnylam case in U.S. District Court concerning cationic lipid patents after Federal Circuit ruling favoring Moderna
- Operational risk: Potential injunctions from European patent claims by GSK could disrupt Spikevax and mRESVIA supply across multiple countries
- Financial risk: Litigation-related monetary damages sought by GSK and others could materially affect cash flow and earnings
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Moderna quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.